Literature DB >> 3003204

The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses.

T W Klein, C A Newton, R Widen, H Friedman.   

Abstract

Previous studies have shown that delta-9-tetrahydrocannabinol (THC) suppresses T-lymphocyte proliferation when added to human cell cultures. We report that THC when added to mouse splenocyte cultures suppressed T-lymphocyte (Con A, PHA) and B-lymphocyte (LPS) mitogen-induced proliferation. Although the ED50 concentrations (5 micrograms/ml; 1.6 X 10(-5)M) of THC were similar for suppressing all three mitogen responses, higher threshold concentrations of drug were required to effect suppression of the T-lymphocyte mitogen responses. Complete suppression of T- and B-lymphocyte responses was achieved with THC concentrations (8 micrograms/ml or 2.6 X 10(-5)M) which were not directly toxic as judged by vital dye exclusion. The hydroxylated metabolite of THC, 11-hydroxy-THC, was observed to be much less potent in the inhibition of lymphocyte proliferation. However, as with the parent compound, B-lymphocyte responses appeared to be the most affected by the drug. Additional studies demonstrated that both T- and B-lymphocyte proliferation is rapidly suppressed following THC treatment, not affected by a 24 hr. pretreatment with THC, and not as readily suppressed by THC in cultures containing 20% serum. Thus, THC appears to inhibit both T- and B-lymphocyte proliferation with B-lymphocyte responses displaying greater inhibition at lower drug concentration. The 11-hydroxy metabolite is much less suppressive in this system than the parent compound.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3003204     DOI: 10.3109/08923978509026487

Source DB:  PubMed          Journal:  J Immunopharmacol        ISSN: 0163-0571


  18 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

Review 3.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

4.  Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.

Authors:  Julie C Williams; Sofia Appelberg; Bruce A Goldberger; Thomas W Klein; John W Sleasman; Maureen M Goodenow
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-23       Impact factor: 4.147

Review 5.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

6.  Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.

Authors:  Rebecca Hartzell Robinson; Joseph J Meissler; Jessica M Breslow-Deckman; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-04       Impact factor: 4.147

Review 7.  Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.

Authors:  Newman Osafo; Oduro K Yeboah; Aaron O Antwi
Journal:  Mol Biol Rep       Date:  2021-04-28       Impact factor: 2.316

Review 8.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

9.  Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Authors:  Cecilia T Costiniuk; Edward Mills; Curtis L Cooper
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

10.  Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells.

Authors:  J Ongrádi; S Specter; A Horváth; H Friedman
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.